Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 7/20 | 0.50 |
| ▸ | ABL1 | P00519 | 7/20 | 0.48 |
| ▸ | EGFR | P00533 | 3/20 | 0.48 |
| ▸ | ABL2 | P42684 | 2/20 | 0.48 |
| ▸ | RET | P07949 | 2/20 | 0.47 |
| ▸ | KIF5B | P33176 | 1/20 | 0.47 |
| ▸ | PTK6 | Q13882 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24458957 | 0.91 | SRC (0.46) | SRCABL1EGFRABL2RET | |
| SCHEMBL24459016 | 0.89 | SRC (0.48) | SRCABL1EGFRABL2RET | |
| SCHEMBL29552045 | 0.89 | RET (0.43) | SRCABL1EGFRABL2RET | |
| SCHEMBL24458601 | 0.88 | RET (0.49) | RETKIF5BKDR | |
| SCHEMBL29552667 | 0.86 | SRC (0.43) | SRCABL1EGFRABL2RET | |
| SCHEMBL29552703 | 0.84 | SRC (0.45) | SRCRETKIF5B | |
| SCHEMBL24459022 | 0.84 | SRC (0.49) | SRCABL1EGFRABL2RET | |
| SCHEMBL24458670 | 0.83 | SRC (0.51) | SRCABL1EGFRABL2RET | |
| SCHEMBL24458360 | 0.82 | ITK (0.54) | KDR | |
| SCHEMBL29552575 | 0.81 | RET (0.43) | SRCABL1EGFRABL2RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154154-A1 | SRC INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS, INC. | 2025-05-15 | — | — | US | disclosed |
| EP-4247816-A1 | SRC INHIBITORS AND USES THEREOF | Relay Therapeutics, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| WO-2022109551-A1 | SRC INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022109551-A1 | SRC INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154154-A1 | SRC INHIBITORS AND USES THEREOF | SRC, LCK, FYN | SRC 1/4885ABL1 5/4885EGFR 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.